CADTH’s pan-Canadian Oncology Drug Review (pCODR) undertakes rigorous, objective reviews of cancer drugs and provides funding recommendations to Canada’s provinces and territories (except Quebec). Funders use this information as one element of their decision-making process to determine if a drug will be eligible for public reimbursement.
pCODR takes into account evidence from a number of sources, including patient groups, drug manufacturers, clinician-based tumour groups, and the pCODR Provincial Advisory Group.
CADTH has developed a pilot initiative that will increase opportunities for clinicians to provide input and feedback and participate in the pCODR process. The expanded initiative will allow for broader clinician participation in providing and enhancing value-added information, not only for the pCODR program but also for the larger discussion of drug funding decisions in Canada.
This section of cadth.ca is devoted to collecting registered clinician input to gain insight into local issues and identify areas of unmet need. This input is incorporated into the pCODR process in a formal and meaningful way, and is used by the pCODR Expert Review Committee (pERC) — a CADTH advisory body — to make funding recommendations.
As a starting point, registered clinicians may wish to consult our FAQs to determine eligibility to participate and to understand the process. Clinicians can then visit the Registration page. Registration is required before input or feedback can be submitted. Successful registration provides access to our secure Collaborative Workspaces page and enables the electronic delivery of documents to CADTH.